| Literature DB >> 35484698 |
Hongming Xu1, Yoon Jin Cha2, Sung Hak Lee3, Jeonghyun Kang4, Tae Hyun Hwang5, Jean R Clemenceau5, Jinhwan Choi5.
Abstract
This study aimed to explore the prognostic impact of spatial distribution of tumor-infiltrating lymphocytes (TILs) quantified by deep learning (DL) approaches based on digitalized whole-slide images stained with hematoxylin and eosin in patients with colorectal cancer (CRC). The prognostic impact of spatial distributions of TILs in patients with CRC was explored in the Yonsei cohort (n = 180) and validated in The Cancer Genome Atlas (TCGA) cohort (n = 268). Two experienced pathologists manually measured TILs at the most invasive margin (IM) as 0-3 by the Klintrup-Mäkinen (KM) grading method and this was compared to DL approaches. Inter-rater agreement for TILs was measured using Cohen's kappa coefficient. On multivariate analysis of spatial TIL features derived by DL approaches and clinicopathological variables including tumor stage, microsatellite instability, and KRAS mutation, TIL densities within 200 μm of the IM (f_im200) remained the most significant prognostic factor for progression-free survival (PFS) (hazard ratio [HR] 0.004 [95% confidence interval, CI, 0.0001-0.15], p = 0.0028) in the Yonsei cohort. On multivariate analysis using the TCGA dataset, f_im200 retained prognostic significance for PFS (HR 0.031 [95% CI 0.001-0.645], p = 0.024). Inter-rater agreement of manual KM grading was insignificant in the Yonsei (κ = 0.109) and the TCGA (κ = 0.121) cohorts. The survival analysis based on KM grading showed statistically significant different PFS in the TCGA cohort, but not the Yonsei cohort. Automatic quantification of TILs at the IM based on DL approaches shows prognostic utility to predict PFS, and could provide robust and reproducible TIL density measurement in patients with CRC.Entities:
Keywords: colorectal cancer; deep learning; prognosis; tumor-infiltrating lymphocytes; whole-slide image
Mesh:
Year: 2022 PMID: 35484698 PMCID: PMC9161341 DOI: 10.1002/cjp2.273
Source DB: PubMed Journal: J Pathol Clin Res ISSN: 2056-4538
Figure 1Overview of the approach taken in this study. Tumor region and TILs are first detected in the H&E‐stained WSI based on DL approaches. We then quantify TILs across and within tumors. The spatial distributions of TILs densities at tumor IMs and tumor core are used to identify patient subgroups with distinct PFS outcome.
Patient characteristics of the Yonsei and TCGA datasets
| Variables | Yonsei ( | TCGA ( |
| |
|---|---|---|---|---|
| Sex | Female | 74 (41.1) | 130 (48.5) | |
| Male | 106 (58.9) | 138 (51.5) | 0.149 | |
| Age (years) | <70 | 28 (15.6) | 178 (66.4) | |
| ≥70 | 152 (84.4) | 90 (33.6) | <0.001 | |
| BMI (kg/m2) | <25 | 134 (74.4) | 54 (20.1) | |
| ≥25 | 46 (25.6) | 150 (56) | ||
| No data | — | 64 (23.9) | <0.001 | |
| CEA (ng/ml) | <5 | 113 (62.8) | — | |
| ≥5 | 67 (37.2) | — | NA | |
| Tumor location | Right colon | 62 (34.4) | 134 (50) | |
| Left colon | 118 (65.6) | 105 (39.2) | ||
| Rectum | — | 19 (7.1) | ||
| No data | — | 10 (3.7) | NA | |
| Complications | No | 145 (80.6) | — | |
| Yes | 35 (19.4) | — | NA | |
| Histological grade | G1 and G2 | 149 (82.8) | — | |
| G3, etc. | 31 (17.2) | — | NA | |
| LVI | Absent | 109 (60.6) | 102 (38.1) | |
| Present | 66 (36.7) | 144 (53.7) | ||
| No data | 5 (2.8) | 22 (8.2) | <0.001 | |
| LN numbers | <12 | 10 (5.6) | 35 (13.1) | |
| ≥12 | 170 (94.4) | 212 (79.1) | ||
| No data | — | 21 (7.8) | <0.001 | |
| Stage | I | — | 39 (14.6) | |
| II | 27 (15) | 105 (39.2) | ||
| III | 153 (85) | 94 (35.1) | ||
| IV | — | 30 (11.2) | <0.001 | |
| MSI | MSS/MSI‐low | 83 (46.1) | 159 (59.3) | |
| MSI‐high | 13 (7.2) | 49 (18.3) | ||
| No data | 84 (46.7) | 60 (22.4) | <0.001 | |
| f_wt | Continuous | 0.1 (0.1) | 0.1 (0.1) | 0.619 |
| f_im200 | Continuous | 0.2 (0.1) | 0.1 (0.1) | <0.001 |
CEA, carcinoembryonic antigen; LN, lymph node; MSS, microsatellite stable; NA, not available.
Univariate and multivariate analyses associated with PFS in the Yonsei dataset (n = 180)
| Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|
| Variables | HR (95% CI) |
| HR (95% CI) |
| |
| Sex | Female | Ref | |||
| Male | 0.83 (0.40–1.72) | 0.622 | |||
| Age (years) | <70 | Ref | |||
| ≥70 | 1.21 (0.42–3.48) | 0.719 | |||
| BMI (kg/m2) | <25 | Ref | |||
| ≥25 | 0.56 (0.21–1.48) | 0.245 | |||
| CEA (ng/ml) | <5 | Ref | |||
| ≥5 | 0.59 (0.26–1.33) | 0.205 | |||
| Tumor location | Right colon | Ref | |||
| Left colon | 1.72 (0.73–4.03) | 0.21 | |||
| Complications | No | Ref | |||
| Yes | 1.11 (0.45–2.73) | 0.812 | |||
| Histological grade | G1 and G2 | Ref | |||
| G3, etc. | 1.03 (0.39–2.72) | 0.939 | |||
| LVI | Absent | Ref | Ref | ||
| Present | 2.71 (1.27–5.80) | 0.009 | 2.60 (1.21–5.55) | 0.013 | |
| No data | 1.81 (0.23–14.03) | 0.569 | 1.36 (0.17–10.57) | 0.766 | |
| LN numbers | <12 | Ref | |||
| ≥12 | 1.51 (0.20–11.12) | 0.684 | |||
| Stage | II | Ref | |||
| III | 2.55 (0.60–10.73) | 0.201 | |||
| MSI | MSS/MSI‐low | Ref | |||
| MSI‐high | 1.18 (0.26–5.30) | 0.822 | |||
| No data | 1.29 (0.60–2.77) | 0.502 | |||
| f_wt | Continuous | 0.095 (0.0007–12.16) | 0.342 | ||
| f_im200 | Continuous | 0.003 (0.0001–0.14) | 0.002 | 0.004 (0.0001–0.15) | 0.0028 |
CEA, carcinoembryonic antigen; LN, lymph node; MSS, microsatellite stable; Ref, reference.
Univariate and multivariable analyses of factors associated with PFS in the TCGA dataset (n = 268)
| Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|
| Variables | HR (95% CI) |
| HR (95% CI) |
| |
| Sex | Female | Ref | |||
| Male | 1.592 (0.992–2.555) | 0.053 | |||
| Age | <70 | Ref | Ref | ||
| ≥70 | 1.708 (1.079–2.705) | 0.022 | 1.994 (1.233–3.222) | 0.004 | |
| BMI (kg/m2) | <25 | Ref | |||
| ≥25 | 1.454 (0.782–2.701) | 0.236 | |||
| No data | 0.896 (0.426–1.887) | 0.774 | |||
| CEA (ng/ml) | <5 | NA | |||
| ≥5 | NA | ||||
| Tumor location | Right colon | Ref | |||
| Left colon | 0.830 (0.504–1.365) | 0.464 | |||
| Rectum | 1.017 (0.428–2.417) | 0.969 | |||
| No data | 1.662 (0.589–4.690) | 0.337 | |||
| Complications | No | NA | |||
| Yes | NA | ||||
| Histological grade | G1 and G2 | NA | |||
| G3, etc. | NA | ||||
| LVI | Absent | Ref | |||
| Present | 1.620 (1.008–2.603) | 0.046 | |||
| No data | 1.338 (0.522–3.424) | 0.543 | |||
| LN numbers | <12 | Ref | Ref | ||
| ≥12 | 0.629 (0.337–1.175) | 0.146 | 0.571 (0.302–1.078) | 0.084 | |
| No data | 0.323 (0.090–1.164) | 0.084 | 0.270 (0.072–1.017) | 0.053 | |
| Stage | I and II | Ref | Ref | ||
| III | 1.598 (0.945–2.702) | 0.080 | 1.557 (0.910–2.662) | 0.105 | |
| IV | 4.062 (2.241–7.361) | <0.001 | 3.342 (1.804–6.191) | 0.0001 | |
| MSI | MSS/MSI‐low | Ref | |||
| MSI‐high | 0.873 (0.457–1.667) | 0.682 | |||
| No data | 1.485 (0.881–2.503) | 0.137 | |||
| f_wt | Continuous | 0.007 (0.0002–0.2793) | 0.0079 | ||
| f_im200 | Continuous | 0.0103 (0.0005–0.1999) | 0.0024 | 0.031 (0.001–0.645) | 0.024 |
CEA, carcinoembryonic antigen; LN, lymph node; MSS, microsatellite stable; NA, not available; Ref, reference.
Figure 2Kaplan–Meier plots for patient subgroup analysis identified by DeepTILs and KM gradings by the pathologists. (A) TIL‐high and ‐low subgroups identified by DeepTILs in the Yonsei cohort. (B, C) TIL‐high and ‐low subgroups identified by KM gradings from (B) pathologist 1 and (C) pathologist 2 in the Yonsei cohort. (D) TIL‐high and ‐low subgroups identified by DeepTILs in TCGA cohort. (E, F) TIL‐high and ‐low subgroups identified by KM gradings from (E) pathologist 1 and (F) pathologist 2 in the TCGA cohort.
Figure 3Kaplan–Meier survival analysis based on combination of subgroups derived from KM grading and DeepTILs. Patients were assigned to four subgroups; TILs high and high, TILs high and low, TILs low and high, and TILs low and low using KM grading by two pathologists and DeepTILs in the Yonsei and TCGA CRC cohorts, respectively. (A) Combination of patient subgroups by pathologist 1 and DeepTILs in the Yonsei cohort. (B) Combination of patient subgroups by pathologist 2 and DeepTILs in the Yonsei cohort. (C) Combination of patient subgroups by pathologist 1 and DeepTILs in the TCGA cohort. (D) Combination of patient subgroups by pathologist 2 and DeepTILs in the TCGA cohort.